PDS Biotechnology Corp (PDSB) stock
PDSBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.89−0.03 (-3.28%)
Close on Nov 17, 2026Market cap $50.03MP/E –Yield –
PDS Biotechnology cash
Cash and short-term investments held at the end of each period.
PDS Biotechnology's cash was $5.60M at Jun 30, 2026. For fiscal 2025 it was $26.71M, down 35.9% from the year before. Over ten years it grew -14.6% a year on average. The highest annual figure on record is $130.19M in fiscal 2015.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.71M | -35.9% |
| FY2024 | Dec 31, 2024 | $41.69M | -26.3% |
| FY2023 | Dec 31, 2023 | $56.56M | -23.4% |
| FY2022 | Dec 31, 2022 | $73.82M | +13.1% |
| FY2021 | Dec 31, 2021 | $65.24M | +126.2% |
| FY2020 | Dec 31, 2020 | $28.84M | +137.1% |
| FY2019 | Dec 31, 2019 | $12.16M | +11628.4% |
| FY2018 | Dec 31, 2018 | $103.70K | -41.0% |
| FY2017 | Dec 31, 2017 | $175.88K | -99.8% |
| FY2016 | Dec 31, 2016 | $106.40M | -18.3% |
| FY2015 | Dec 31, 2015 | $130.19M | +848.3% |
| FY2014 | Dec 31, 2014 | $13.73M | +74.7% |
| FY2013 | Dec 31, 2013 | $7.86M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $5.60M | -82.4% |
| Q1 FY2026 | Mar 31, 2026 | $21.66M | -45.8% |
| Q4 FY2025 | Dec 31, 2025 | $26.71M | -35.9% |
| Q3 FY2025 | Sep 30, 2025 | $26.20M | -47.3% |
| Q2 FY2025 | Jun 30, 2025 | $31.87M | -44.8% |
| Q1 FY2025 | Mar 31, 2025 | $39.98M | -40.0% |
| Q4 FY2024 | Dec 31, 2024 | $41.69M | -26.3% |
| Q3 FY2024 | Sep 30, 2024 | $49.75M | -8.3% |
| Q2 FY2024 | Jun 30, 2024 | $57.73M | -4.8% |
| Q1 FY2024 | Mar 31, 2024 | $66.63M | +2.2% |
| Q4 FY2023 | Dec 31, 2023 | $56.56M | -23.4% |
| Q3 FY2023 | Sep 30, 2023 | $54.25M | -24.3% |
| Q2 FY2023 | Jun 30, 2023 | $60.62M | +14.4% |
| Q1 FY2023 | Mar 31, 2023 | $65.20M | +10.7% |
| Q4 FY2022 | Dec 31, 2022 | $73.82M | +13.1% |
| Q3 FY2022 | Sep 30, 2022 | $71.64M | +2.7% |
| Q2 FY2022 | Jun 30, 2022 | $52.98M | -29.1% |
| Q1 FY2022 | Mar 31, 2022 | $58.88M | +135.2% |
| Q4 FY2021 | Dec 31, 2021 | $65.24M | +126.2% |
| Q3 FY2021 | Sep 30, 2021 | $69.74M | +108.4% |
| Q2 FY2021 | Jun 30, 2021 | $74.75M | +341.4% |
| Q1 FY2021 | Mar 31, 2021 | $25.04M | +19.0% |
| Q4 FY2020 | Dec 31, 2020 | $28.84M | +137.1% |
| Q3 FY2020 | Sep 30, 2020 | $33.47M | +92.3% |
| Q2 FY2020 | Jun 30, 2020 | $16.93M | -22.1% |
| Q1 FY2020 | Mar 31, 2020 | $21.04M | -20.9% |
| Q4 FY2019 | Dec 31, 2019 | $12.16M | +11628.4% |
| Q3 FY2019 | Sep 30, 2019 | $17.41M | +12100.7% |
| Q2 FY2019 | Jun 30, 2019 | $21.73M | +5264.3% |
| Q1 FY2019 | Mar 31, 2019 | $26.59M | +3127.0% |
| Q4 FY2018 | Dec 31, 2018 | $103.70K | -41.0% |
| Q3 FY2018 | Sep 30, 2018 | $142.67K | -99.9% |
| Q2 FY2018 | Jun 30, 2018 | $405.16K | -99.6% |
| Q1 FY2018 | Mar 31, 2018 | $824.07K | -99.1% |
| Q4 FY2017 | Dec 31, 2017 | $175.88K | -99.8% |
| Q3 FY2017 | Sep 30, 2017 | $97.31M | -13.7% |
| Q2 FY2017 | Jun 30, 2017 | $108.71M | – |
| Q1 FY2017 | Mar 31, 2017 | $95.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $106.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $112.78M | – |
See a number that looks wrong?